Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
ConditionMultiple Myeloma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorNanjing IASO Biotechnology Co., Ltd.
About this trial
This is a multicenter, open-label, single-arm, long-term follow-up clinical study. All patients who have received Equecabtagene Autoleucel Injection treatment will be enrolled.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
1. Receipt of another lentiviral vector-based cell or gene therapy (either commercialized product or investigational product in a clinical tiral) between the infution of Equecabtagene Autoleucel Injection and the signing informed consent.
Trial population
All patients who have received Equecabtagene Autoleucel Injection treatment. Patients who participated in pre-marketing clinical studies or post-marketing real-world studies with this product can only be enrolled after completing or prematurely withdrawing from their original studies.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
No Intervention (subjects were previously treated with Equecabtagene Autoleucel Injection) )
Other interventionThis study is observational study and all participants will be obsreved with no intervention.
Treatment groups
1,500 Participants
are divided into 1 treatment groupGroup A: All patients received Equecabtagene Autoleucel Injection1 intervention
Trial outcomes
Primary outcomes
1
To evaluate the safety profile of Equecabtagene Autoleucel Injection in treated patients.
Time frame
Up to 15 years from enrollmentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov